Cover Image

The Immunogenicity and Safety of CYD-Tetravalent Dengue Vaccine (CYD-TDV) in Children and Adolescents: A Systematic Review

Aim: to assess the immunogenicity and safety of CYD-tetravalent dengue vaccine (CYD-TDV) in children. Methods: comprehensive literature searches were conducted on various databases. Randomized-controlled trials on children with CYD-TDV as intervention were selected based on inclusion and exclusion c...

Full description

Saved in:

Bibliographic Details
Main Authors:	Raksheeth Agarwal (Author), Mardiastuti H Wahid (Author), Oliver E Yausep (Author), Sharon Hanmy Angel (Author), Angga W Lokeswara (Author)
Format:	Book
Published:	Interna Publishing, 2017-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials
by: Ngoc Huu Tran, et al.
Published: (2019)

Analysis of the evidence on the efficacy and safety of CYD-TDV dengue vaccine and its potential licensing and implementation through Mexico´s Universal Vaccination Program
by: Mauricio Hernández-Ávila, et al.
Published: (2016)

Analysis of the evidence about the efficacy and safety of the CYD-TDV dengue vaccine and its potential licensing and implementation within the Mexican Universal Vaccination Program
by: Mauricio Hernández-Ávila, et al.
Published: (2016)

Effectiveness of mass dengue vaccination with CYD-TDV (Dengvaxia®) in the state of Paraná, Brazil: integrating case-cohort and case-control designsResearch in context
by: Fredi Alexander Diaz-Quijano, et al.
Published: (2024)

Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City
by: Shibadas Biswal, et al.
Published: (2021)

Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination
by: Claire Vigne, et al.
Published: (2017)

Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial
by: Mark Turner, et al.
Published: (2020)

Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-naïve adults
by: Susan B. Manoff, et al.
Published: (2019)

A recombinant live attenuated tetravalent vaccine for the prevention of dengue
by: Bruno Guy, et al.
Published: (2017)

Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study.
by: Vianney Tricou, et al.
Published: (2023)

In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.
by: Stephen S Whitehead, et al.
Published: (2017)

Efficacy of tetravalent dengue vaccine: A systematic review and meta-analysis
by: Ashish Wasudeo Khobragade, et al.
Published: (2021)

Challenges to the Design of Clinical Trials for Live-Attenuated Tetravalent Dengue Vaccines.
by: Philip K Russell, et al.
Published: (2016)

Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax).
by: Claire Y-H Huang, et al.
Published: (2013)

Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials.
by: Sophia Gailhardou, et al.
Published: (2016)

Safety issues from a Phase 3 clinical trial of a live-attenuated chimeric yellow fever tetravalent dengue vaccine
by: Scott B. Halstead
Published: (2018)

An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life
by: Sanjay S. Patel, et al.
Published: (2023)

A case-control study to determine the effectiveness of a tetravalent dengue vaccine in the state of Paraná, Brazil
by: José Cássio de Moraes, et al.
Published: (2022)

Development and evaluation of a tetravalent botulinum vaccine
by: Dan-Yang Shi, et al.
Published: (2022)

Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003).
by: Laura J White, et al.
Published: (2021)

A randomized, open-label clinical trial to evaluate immunogenicity and safety of an indigenously developed DTwP-Hib tetravalent combination vaccine (Easyfour®-TT) with Quadrovax® in Indian infants
by: Lalitendu Mohanty, et al.
Published: (2017)

Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial
by: Juliana Park, et al.
Published: (2021)

Early Transcriptional Signatures of the Immune Response to a Live Attenuated Tetravalent Dengue Vaccine Candidate in Non-human Primates.
by: Fiona R Strouts, et al.
Published: (2016)

Immunogenicity and safety of the first indigenously developed Indian tetravalent influenza vaccine (split virion) in healthy adults ≥ 18 years of age: A randomized, multicenter, phase II / III clinical trial
by: Shrikant Sharma, et al.
Published: (2018)

An Epitope-Substituted DNA Vaccine Improves Safety and Immunogenicity against Dengue Virus Type 2.
by: Chung-Tao Tang, et al.
Published: (2015)

Immunogenicity and safety of the first indigenously developed Indian tetravalent influenza vaccine (split virion) in healthy children (6 months to 17 years of age): a randomized, multicenter, phase III clinical trial
by: Sumantra Sarkar, et al.
Published: (2021)

Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions
by: Philippe Moris, et al.
Published: (2019)

Letter to the editor: Safety and immunogenicity of a novel recombinant rabies vaccine
by: Anurag Agarwal, et al.
Published: (2022)

Immunogenicity of fractional doses of tetravalent a/c/y/w135 meningococcal polysaccharide vaccine: results from a randomized non-inferiority controlled trial in Uganda.
by: Philippe J Guerin, et al.
Published: (2008)

Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype.
by: Stefan W Metz, et al.
Published: (2018)

Using the tetravalent meningococcal polysaccharide-protein conjugate vaccine in the prevention of meningococcal disease
by: Sanford R Kimmel
Published: (2008)

Immunogenicity, safety and tolerability of intradermal influenza vaccines
by: Ivan F. N. Hung, et al.
Published: (2018)

Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine
by: Eva Hong, et al.
Published: (2017)

Immunogenicity and safety of a trivalent inactivated influenza vaccine
by: Eddy Fadlyana, et al.
Published: (2011)

The effect of a booster dose of HPV tetravalent vaccine after 51 months: implications for extended vaccination schedules
by: Eduardo Lazcano-Ponce, et al.
Published: (2018)

Safety and immunogenicity of the first Kazakh inactivated vaccine for COVID-19
by: Ainur Nurpeisova, et al.
Published: (2022)

Safety and immunogenicity of Clostridium difficile toxoid vaccine in Japanese adults
by: Osamu Matsuoka, et al.
Published: (2018)

EVALUATION OF REACTOGENICITY, SAFETY AND IMMUNOGENICITY OF INACTIVATED MONOVALENT VACCINE IN CHILDREN
by: A.N. Mironov, et al.
Published: (2010)

A Meta-Analysis on the Safety and Immunogenicity of Covid-19 Vaccines
by: Rasha Ashmawy, et al.
Published: (2022)

EVALUATION OF REACTOGENICITY, SAFETY AND IMMUNOGENICITY OF INACTIVATED MONOVALENT VACCINE IN CHILDREN
by: A.N. Mironov, et al.
Published: (2010)